ANGN » Topics » Research and Development

These excerpts taken from the ANGN 10-K filed Jan 29, 2010.

Research and Development

          In 2009, Medical Graphics continued to develop new products and implemented product improvements designed to enhance product reliability and improve margins. The Company’s research and development initiatives are targeted for hospitals, clinics and physician’s offices as well as the health and fitness club markets. An integral component of the Company’s future growth strategies includes developing and introducing additional new products.

          Research and development expenses were $3.2 million and $2.4 million for the years ended October 31, 2009 and 2008, respectively.

          Research and Development

          Research and development expenses for 2009 increased by 29.3%, or $714,000, to $3.2 million compared to the same period in 2008.

          Personnel-related costs increased by $467,000, or 27.7%, in 2009, compared to the same period in 2008 as the Company expanded its investment in new product development and quality assurance. In addition, project expenses associated with new product development increased by $198,000 for 2009 compared to 2008. The Company introduced the all-new, updated CCM Express®, which provides accurate resting energy expenditure measurements (“REE”) for either ventilated or spontaneously breathing patients during fiscal 2009. The Company’s current new product development initiatives include products targeted for hospital intensive care units, cardiology, dietary, asthma, allergy and primary care physicians, health and fitness club professionals, as well as international markets. In addition, the Company is also developing new functionality and new technologies for use in existing products.

This excerpt taken from the ANGN 10-Q filed Jun 12, 2009.

Research and Development

          Research and development expenses for the three and six months ended April 30, 2009 were $729,000 and $1.5 million, respectively, compared to $708,000 and $1.3 million, respectively, for the same period in 2008.

          Payroll and benefits expense increased by $191,000 for the six months ended April 30, 2009 compared to the same period in 2008 as the Company expanded its investment in new product development and quality assurance. Project expenses associated with new products increased by $31,000 due to the launch of the updated CCM Express in the first quarter of 2009. This was partially offset by a decrease in legal fees of $30,000 due to less patent-related work compared to the prior year. The Company’s current new product development initiatives include products targeted for hospital intensive care units, cardiology, dietary, asthma, allergy and primary care physicians, health and fitness club professionals, as well as international markets.

This excerpt taken from the ANGN 10-Q filed Mar 17, 2009.

Research and Development

          Research and development expenses for the three months ended January 31, 2009 increased by 27.4%, or $169,000, to $787,000 from $618,000 for the same period in 2008.

          Payroll and benefits costs increased $105,000 over the prior period as some current employees were transferred into this area from selling and marketing. This increase was partially offset by a $31,000 decrease in legal expenses related to intellectual property as the Company had incurred higher expenses in the 2008 first quarter related to the ongoing preparation and filing of patent and trademark applications.

          Project expenses associated with new products increased by $48,000, or 89%, for the three months ended January 31, 2009 compared to the same period in 2008 as the Company prepared for and implemented the release of the all new CCM Express.

          The Company’s current product development initiatives include new or updated products targeted for hospital intensive care units, cardiology, dietary, asthma, allergy and primary care physicians, and health and fitness club professionals. In addition to selling these products in the United States, the Company intends to introduce some of these new products internationally as well as continuing to expand the international distribution of its existing products.

These excerpts taken from the ANGN 10-K filed Jan 26, 2009.

Research and Development

          In 2008, Medical Graphics continued to develop new products and implemented product improvements designed to enhance product reliability and improve margins. The Company’s research

8


and development initiatives are targeted for hospitals, clinics, physician’s offices and the health and fitness club markets. An integral component of the Company’s future growth strategies includes developing and introducing additional new products.

          Research and development expenses were $2.4 million and $2.8 million for the years ended October 31, 2008 and 2007, respectively.

Research and Development



          In
2008, Medical Graphics continued to develop new products and implemented
product improvements designed to enhance product reliability and improve
margins. The Company’s research



8







and
development initiatives are targeted for hospitals, clinics, physician’s
offices and the health and fitness club markets. An integral component of the
Company’s future growth strategies includes developing and introducing
additional new products.



          Research
and development expenses were $2.4 million and $2.8 million for the years ended
October 31, 2008 and 2007, respectively.



          Research and Development

          Research and development expenses for 2008 decreased by 13.5%, or $383,000, to $2.4 million compared to the same period in 2007.

          Personnel-related costs decreased by $261,000 in 2008, compared to the same period in 2007 as the Company reduced headcount in the current year. In addition, project expenses associated with new product development decreased by $178,000 for 2008 compared to 2007. The Company introduced the Platinum EliteTM during the second quarter of 2008. Much of the spending on the testing of the Platinum EliteTM occurred during fiscal 2007. The Company still continues to focus on other new product development initiatives, including products targeted for cardiology, dietary, asthma, allergy and primary care physicians, health and fitness club professionals, as well as international markets. In addition, the Company is also developing new functionality and new technologies for use in existing products.

          Research
and Development



          Research
and development expenses for 2008 decreased by 13.5%, or $383,000, to $2.4
million compared to the same period in 2007.



          Personnel-related
costs decreased by $261,000 in 2008, compared to the same period in 2007 as the
Company reduced headcount in the current year. In addition, project expenses
associated with new product development decreased by $178,000 for 2008 compared
to 2007. The Company introduced the Platinum EliteTM during the
second quarter of 2008. Much of the spending on the testing of the Platinum
EliteTM occurred during fiscal 2007. The Company still continues to
focus on other new product development initiatives, including products targeted
for cardiology, dietary, asthma, allergy and primary care physicians, health
and fitness club professionals, as well as international markets. In addition,
the Company is also developing new functionality and new technologies for use
in existing products.



This excerpt taken from the ANGN 8-K filed Feb 6, 2008.

Research and Development

 

                Research and development expenses for the 2007 fourth quarter increased by 9.6%, or $65,000, to $745,000 from $680,000 for the same period in 2006.

 

                Project expenses associated with new products increased by $53,000, or 40.8%, for the 2007 fourth quarter compared to the same period in 2006.  The Company’s current new product development initiatives include products targeted for hospital intensive care units, cardiology, dietary, asthma, allergy and primary care physicians, health and fitness club professionals, as well as international markets.  These new products are currently completing clinical evaluation and are planned for release during fiscal 2008.  In addition, the Company is also developing new functionality and new technologies for use in existing products.  There was no material change to expenses related to payroll and personnel related expenses for the 2007 fourth quarter compared to the same period in 2006.

 

These excerpts taken from the ANGN 10-K filed Jan 29, 2008.

Research and Development

 

Research and development expenses for 2007 increased by 19.1%, or $453,000, to $2.8 million from $2.4 million compared to the same period in 2006 and $2.1 million in 2005.

 

Costs related to new personnel contributed to an increase of $249,000 in research and development expenses for 2007, compared to the same period in 2006.  In addition, project expenses associated with new product development increased by $170,000 for 2007 compared to 2006.  The Company introduced the CCM ExpressTM during the fourth quarter of 2007.  The CCM ExpressTM is targeted at monitoring and mechanical ventilator management applications in intensive care units.  Other new product development initiatives include products targeted for cardiology, dietary, asthma, allergy and primary care physicians, health and fitness club professionals, as well as international markets.  Some of these new products are currently completing clinical evaluation and are planned for release in fiscal 2008.  In addition, the Company is also developing new functionality and new technologies for use in existing products.

 

Research and development expenses increased 14.8% in 2006 compared to 2005.  Expenses for new personnel of $274,000 accounted for the majority of the increase in research and development costs for 2006.

 

Research and Development



 



Research and development expenses for 2007 increased
by 19.1%, or $453,000, to $2.8 million from $2.4 million compared to the same
period in 2006 and $2.1 million in 2005.



 



Costs related to new personnel contributed to an
increase of $249,000 in research and development expenses for 2007, compared to
the same period in 2006.  In addition,
project expenses associated with new product development increased by $170,000
for 2007 compared to 2006.  The Company
introduced the CCM ExpressTM during the fourth quarter of 2007.  The CCM ExpressTM is targeted at
monitoring and mechanical ventilator management applications in intensive care
units.  Other new product development
initiatives include products targeted for cardiology, dietary, asthma, allergy
and primary care physicians, health and fitness club professionals, as well as
international markets.  Some of these new
products are currently completing clinical evaluation and are planned for
release in fiscal 2008.  In addition, the
Company is also developing new functionality and new technologies for use in
existing products.



 



Research and development expenses increased 14.8% in
2006 compared to 2005.  Expenses for new
personnel of $274,000 accounted for the majority of the increase in research
and development costs for 2006.



 



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki